Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
130
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment

Domenico Pennaa Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy;b Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3102-422XView further author information
ORCID Icon,
Alessia Tieghia Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information
,
Riccardo Vallic Pathology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information
&
Francesco Merlia Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information
Pages 1723-1726 | Received 27 Feb 2023, Accepted 04 Jul 2023, Published online: 13 Jul 2023

References

  • Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–362. doi:10.1111/j.1365-2141.2007.06807.x
  • Harrison JS, Corcoran KE, Joshi D, et al. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol. 2006;81(1):51–58. doi:10.1002/ajh.20439
  • Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145–162. doi:10.1002/ajh.26050
  • Tefferi A, Partain DK, Palmer JM, et al. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018;93(5):649–654. doi:10.1002/ajh.25053
  • Rizzi R, Pastore D, Liso A, et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma. 2004;45(3):561–566. doi:10.1080/10428190310001597982
  • Vergara-Lluri ME, Piatek CI, Pullarkat V, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014;45(11):2183–2191. doi:10.1016/j.humpath.2014.07.017
  • Pullarkat V, Bass RD, Gong JZ, et al. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72(1):8–12. doi:10.1002/ajh.10258
  • Marcellino B, El Jamal SM, Mascarenhas JO. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol. 2018;16(9):619–626.
  • Piatek CI, Vergara-Lluri ME, Pullarkat V, et al. Autoimmune myelofibrosis: clinical features, course, and outcome. Acta Haematol. 2017;138(3):129–137. doi:10.1159/000479103
  • Damsky W, Peterson D, Ramseier J, et al. The emerging role of janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814–826. doi:10.1016/j.jaci.2020.10.022
  • Clark JD, Flanagan ME, Telliez JB. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi:10.1021/jm401490p
  • Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory chronic graft-versus-Host disease. N Engl J Med. 2021;385(3):228–238. doi:10.1056/NEJMoa2033122
  • Camós M, Arellano-Rodrigo E, Abelló D, et al. Idiopathic myelofibrosis associated with classic polyarteritis nodosa. Leuk Lymphoma. 2003;44(3):539–541. doi:10.1080/1042819021000046849
  • Otoukesh S, Song JY, Mojtahedzadeh M, et al. Refractory primary autoimmune myelofibrosis treated with ruxolitinib. Am J Hematol. 2021;96(8):E283–E285. doi:10.1002/ajh.26208
  • O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550. doi:10.1016/j.immuni.2012.03.014Schwartz
  • Kanno DM, Villarino Y, Ward A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.